Epstein-Barr virus (EBV) infects and persists through a four-stage life cycle: it enters oral epithelial cells and B lymphocytes, establishes latency inside memory B cells, reactivates under immune pressure, and sheds into saliva to infect new hosts. This cycle explains why EBV is nearly universal and incurable. Understanding the EBV life cycle reveals how a virus that infects roughly 95 percent of adults worldwide maintains lifelong persistence without usually causing disease.
Entry and the salivary bridge
EBV spreads primarily through saliva. Kissing, sharing utensils, and close contact move infectious virus from a shedding host to a susceptible one. The virus enters through the oropharynx, where it must cross epithelial barriers and reach B cells to establish infection.
The entry mechanism depends on a viral envelope glycoprotein called gp350. This protein binds CD21, a receptor found on B lymphocytes and some epithelial cells. A second glycoprotein complex, gp42 with gH/gL, triggers membrane fusion. The choice of entry route changes the fusion machinery, a detail that matters for vaccine design.
Infection begins in oral epithelial cells, though whether EBV replicates there first or passes through to B cells remains debated. Most models favor direct B-cell infection in tonsillar tissue, with epithelial amplification contributing to later shedding. Once inside a B cell, the virus drives the cell to divide, expanding the infected pool.
This is the lytic phase's opening act. Infected B cells produce new virions, rupture, and release virus into saliva. Fever, sore throat, and swollen lymph nodes during infectious mononucleosis reflect this immune response to the initial burst of viral replication.
Latency: the memory B-cell reservoir
EBV does not stay lytic. Instead it shifts into latency, a dormant state that lets it persist for the host's lifetime. The virus settles into memory B cells, the same long-lived cells that hold immunological memory for decades.
Latency is not silent. EBV expresses a small set of latency proteins, including EBNA1, LMP1, and LMP2A, depending on the latency program. EBNA1 maintains the viral episome—a circular DNA molecule that replicates alongside host DNA. LMP1 mimics an active growth receptor, and LMP2A blocks signals that would otherwise trigger viral reactivation.
Four latency programs exist in different cell contexts. Type I expresses only EBNA1 and appears in memory B cells. Type III expresses all latency proteins and occurs during acute infection. This switching between programs reflects a trade-off: more viral protein expression maintains the infected state but exposes the virus to immune attack. Fewer proteins hide the virus better but leave it vulnerable to elimination.
The memory B-cell reservoir is the core of EBV's persistence strategy. By occupying cells designed to survive for years, the virus guarantees its own survival. This reservoir is why EBV cannot be cleared and why reactivation remains possible after decades.
Reactivation and shedding
Reactivation occurs when immune control weakens or when B cells differentiate. The virus switches from latent to lytic, produces new virions, and sheds them into saliva. Shedding can occur without symptoms and is the primary transmission route.
Most reactivation events are asymptomatic. Healthy adults with latent EBV shed virus intermittently in saliva, often without noticing. Immunosuppression, stress, and other infections can increase shedding frequency. In transplant recipients, reactivation can cause post-transplant lymphoproliferative disorder, a serious complication driven by uncontrolled B-cell proliferation.
The lytic cycle produces a cascade of gene products. Immediate-early proteins (BZLF1 and BRLF1) trigger the switch. Early proteins replicate viral DNA. Late proteins build structural components. Each stage offers a potential drug target, though no approved therapy currently targets latent EBV.
Shedding is highest in the first year after primary infection and declines over time, but never reaches zero. The virus maintains a low-level presence in saliva that keeps transmission possible throughout life.
Timeline of the EBV life cycle:
| Stage | Timeframe | Location | Key Event |
|---|---|---|---|
| Primary infection | Days 0–7 | Oropharynx, tonsils | B-cell entry via CD21 |
| Acute replication | Days 7–30 | B cells, epithelial cells | Lytic burst, mononucleosis symptoms |
| Latency establishment | Weeks 2–8 | Memory B cells | Viral episome maintained |
| Chronic latency | Months to decades | Memory B cells | Intermittent reactivation |
| Reactivation | Variable | B cells, epithelium | Lytic shedding into saliva |
| Transmission | Ongoing | Saliva | New host infection |
Quantified context: who carries EBV and when
EBV is one of the most successful human viruses. In the United States, about 50 percent of children are infected by age 5. By adulthood, 90 to 95 percent of people carry the virus. Worldwide seropositivity in adults approaches 95 percent.
Primary infection timing shapes disease. Children usually seroconvert without symptoms or with mild illness. Adolescents and young adults who acquire EBV develop infectious mononucleosis in 30 to 50 percent of cases. The classic presentation includes fever, pharyngitis, and lymphadenopathy lasting weeks.
Infectious mononucleosis peaks between ages 15 and 24 in high-income countries. The incubation period is roughly 4 to 6 weeks. Fatigue can persist for months but rarely beyond six. Splenic enlargement occurs in many cases, and rupture—though rare—is a medical emergency.
EBV is associated with several malignancies. It is found in nearly 100 percent of endemic Burkitt lymphoma cases, a subset of Hodgkin lymphoma, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disorder. The virus does not cause these cancers alone; genetic and environmental cofactors matter. This association is why EBV research extends beyond infectious disease into oncology.
Edge cases: when the cycle goes wrong
The standard EBV life cycle assumes a healthy immune system. Several edge cases break this pattern.
Severe combined immunodeficiency and other T-cell defects allow unchecked B-cell proliferation after EBV infection. X-linked lymphoproliferative disease, caused by mutations in the SH2D1A gene, leads to fatal mononucleosis in affected boys. These conditions reveal how dependent EBV control is on intact T-cell immunity.
Chronic active EBV is a rare disorder in which lytic replication persists with high viral loads and organ damage. It is more common in East Asia and can progress to hemophagocytic lymphohistiocytosis, a life-threatening inflammatory syndrome.
Post-transplant lymphoproliferative disorder arises when immunosuppressive drugs disable T cells that normally contain infected B cells. The virus-driven proliferation can range from benign hyperplasia to aggressive lymphoma. Reducing immunosuppression is often the first intervention.
Red flag: splenic pain or left upper quadrant tenderness after mononucleosis may signal splenic enlargement or rupture. Red flag: persistent fever beyond three weeks in a patient with EBV warrants evaluation for complications. Red flag: new lymphadenopathy or night sweats months after mononucleosis merit lymphoma workup. Red flag: EBV reactivation in a transplant recipient requires immediate clinical assessment.
Misconceptions about the EBV life cycle
Several myths persist about how EBV behaves.
Misconception one: EBV stays dormant and never reactivates. In reality, subclinical reactivation occurs intermittently in most carriers. Shedding is common and usually harmless.
Misconception two: mononucleosis means lifelong severe fatigue. Most people recover fully. A minority experience prolonged fatigue, but the virus does not cause chronic fatigue syndrome in most cases, though research continues into possible links.
Misconception three: EBV is highly contagious like measles. Transmission requires close contact with saliva. Casual contact rarely spreads the virus. This explains outbreaks in college settings and among young children.
Misconception four: a positive EBV test means active infection. Antibody patterns distinguish past from current infection. IgM against viral capsid antigen suggests recent infection; IgG against EBNA1 suggests past infection.
A counterintuitive detail: the virus that causes mononucleosis is not the same form that persists. The lytic burst that makes you sick is a side effect of the virus establishing latency. The symptoms come from immune activation, not from the latent virus itself. By the time antibodies appear, the virus is already settling into its long-term home.
Practical actions and thresholds
There is no vaccine and no approved antiviral for latent EBV. Management focuses on recognizing complications and avoiding triggers for reactivation.
For most people with mononucleosis, rest and supportive care suffice. Avoid contact sports for at least four weeks after symptom onset because of splenic rupture risk. Some clinicians use imaging to confirm splenic size before clearing athletes.
For transplant recipients, EBV viral load monitoring guides immunosuppression adjustments. Thresholds vary by center. A rising viral load with symptoms prompts intervention. There is no single universal cutoff; protocols differ.
For people with suspected immunodeficiency, EBV serology and viral load testing help characterize risk. Early recognition of X-linked lymphoproliferative disease or chronic active EBV changes management.
Comparison of EBV testing approaches:
| Test | What it detects | Best use |
|---|---|---|
| VCA-IgM | Recent infection | Acute mononucleosis |
| VCA-IgG | Past or current infection | Immunity status |
| EBNA-IgG | Past infection | Distinguishing acute from past |
| Viral load (PCR) | Active replication | Transplant monitoring |
| Heterophile antibody | Mononucleosis | Quick screening (less specific in children) |
No drug is approved to eliminate latent EBV. Research into vaccines targeting gp350 and into antiviral compounds against lytic replication continues. Some early trials explore T-cell therapies for EBV-driven cancers, but these remain experimental.
Limitations and open questions
The EBV life cycle is well characterized at the cellular level but poorly understood at the population level. Why some people develop mononucleosis and others do not remains unclear. The role of viral strain variation, host genetics, and microbiome differences is an active research area.
The link between EBV and multiple sclerosis has strengthened in recent studies, but causality is not proven. The virus may be a necessary but insufficient factor. This distinction matters for interpreting headlines and for vaccine development.
Latency reversal strategies aim to wake the virus and then kill it, but no approach has succeeded in eliminating the reservoir. The memory B-cell niche is deep and well protected.
Animal models are limited. EBV infects humans and some non-human primates, but no small animal model reproduces the full cycle. This slows vaccine and drug development.
The EBV life cycle is a masterclass in viral persistence. It combines efficient transmission, immune evasion, and a reservoir that lasts a lifetime. Understanding each stage explains why the virus is so common and why it remains so hard to defeat.